Search Blog
December 2013
« Nov   Jan »


Traders Buzz: Oracle Corporation, General Electric Company, Ariad Pharmaceuticals, Vertex Pharmaceuticals Incorporated


By PrimeTimeMedia LLC

New York, December 19, 2013 / Accesswire / – Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Oracle Corporation(NYSE:ORCL), General Electric Company (NYSE:GE), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

General Electric Company (NYSE:GE) shares decreased 0.73% to $27.21 in the pre-market hour. The company on Dec. 18 said it expects profit from aviation, healthcare and other industrial units to rise at least 10 percent next year as it aggressively invests in manufacturing while shrinking its finance arm. The conglomerate said it expects company-wide profit to rise in the single digits next year, and that it was on track to cut its finance unit’s share of total profit to 30 percent by 2015. Total revenue for 2014 should range from flat to a 5 percent increase, GE said. Analysts, on average, expect GE to increase earnings by about 6 percent next year to $1.74 per share, according to Thomson Reuters I/B/E/S. Revenue is expected to rise by nearly 3 percent in 2014 to $149.7 billion.

Additionally, GE Capital, Corporate Retail Finance on Dec. 16 announced it is administrative agent on a $250 million senior revolving credit facility for Dunham’s Athleisure Corporation, a leading sporting goods retailer. The proceeds will support ongoing working capital needs and new store growth.

Free Urgent Insider Catalyst Report For GE Available Here: (Or Copy and paste the URL into your browser)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares climbed 19.71% to $4.98 following circulation of the agenda. The European Medicines Agency will review Ariad’s Iclusig at its December meeting, according to a meeting agenda posted to the regulator’s website.

Additionally, Levi & Korsinsky on Dec. 5 announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIA, stock between Dec. 12, 2011 and Oct. 8, 2013. The Complaint alleges that throughout the Class Period defendants made false and misleading statements regarding the safety and efficacy of the leukemia drug Iclusig.

Free Urgent Insider Catalyst Report For ARIA Available Here: (Or Copy and paste the URL into your browser)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares declined 4.33% to $65.66 in the pre-market hour. The company on Dec. 19 announced data from a Phase 3 study of ivacaftor in 69 people 6 years of age and older with cystic fibrosis (CF) who have the R117H mutation. In the study, the mean absolute treatment difference in the change from baseline in percent predicted FEV1 between treatment with ivacaftor and placebo was 2.1 percentage points (p=0.20) and the mean relative treatment difference in percent predicted FEV1 was 5.0 percent (p = 0.06) through the 24-week treatment period among all patients (intent-to-treat analysis).

The study did not meet its primary endpoint of the absolute change from baseline in FEV1 (percent predicted forced expiratory volume in one second, FEV1) throughout the treatment period for ivacaftor compared to placebo across all patients. A pre-specified subset analysis in patients 18 years of age and older (n=50) showed statistically significant improvements in lung function and other key secondary endpoints.

Free Urgent Insider Catalyst Report For VRTX Available Here: (Or Copy and paste the URL into your browser)

Oracle Corporation(NYSE:ORCL) shares increased 2.34% to $35.41 in the pre-market hour. The company on Dec. 18 announced that both fiscal 2014 Q2 GAAP and non-GAAP total revenues were up 2% to $9.3 billion. GAAP net income was down 1% to $2.6 billion, while non-GAAP net income was up 1% to $3.2 billion. GAAP earnings per share were up 5% to $0.56, while non-GAAP earnings per share were up 7% to $0.69. GAAP operating cash flow on a trailing twelve-month basis was $15.2 billion.

 Free Urgent Insider Catalyst Report For ORCL Available Here: (Or Copy and paste the URL into your browser) is an investment community that Focuses on MicroCap Securities. is an  authorative authentic Google News Site and  Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit for more details. Get an edge on the market with our Premium News Alerts   that are FREE for a limited time at Follow us on Facebook: Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126 (SMS alerts are free, however data rates may apply, check your wireless plan for details.).